Home ›
Non-Small Cell (NSCLC) Lung Cancer Trials ›
NCT03645928
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Trial Details
NCT ID NCT03645928 Phase PHASE2
Sponsor Iovance Biotherapeutics, Inc.
Status RECRUITING
Cancer Type Non-Small Cell (NSCLC) Lung Cancer
Interventions Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab Locations (sample) La Jolla, California, United States|32.84727,-117.2742 Los Angeles, California, United States|34.05223,-118.24368 Los Angeles, California, United States|34.05223,-118.24368 Denver, Colorado, United States|39.73915,-104.9847 New Haven, Connecticut, United States|41.30815,-72.92816
Key Eligibility Criteria
Must have a confirmed diagnosis of malignancy of their receptive histologies: unresectable or metastatic melanoma Stage IIIC to IV (Cohorts 1A,1B a… Cohorts 1A, 1D, 2A, 3A, 3D and 3E: If previously treated, patients must have progressed on or after most recent therapy and must not have received … Cohorts 1B, 1C, 3B, and 3C: Unresectable or metastatic melanoma patients in Cohorts 1B or 1C must have previously received systemic therapy with a … Must have at least 1 resectable lesion For full eligibility, visit ClinicalTrials.gov .